证券代码：688177 证券简称：百奥泰 公告编号：2025-068 百奥泰生物制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 24 日 （星期一） 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 17 日（星期一）至 11 月 21 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bio-thera.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 百奥泰生物制药股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、 ...

Core Points - The stock price of Baiotai increased by 2.03% on November 12, reaching 26.59 yuan per share, with a total market capitalization of 11.01 billion yuan [1] - Baiotai's stock has risen by 37.20% year-to-date, but has seen a decline of 1.52% over the past 20 days and 14.25% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Baiotai achieved a revenue of 684 million yuan, representing a year-on-year growth of 17.57% [2] - The net profit attributable to the parent company was -224 million yuan, showing a year-on-year increase of 38.72% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Baiotai was 9,397, a decrease of 0.89% from the previous period [2] - The average number of circulating shares per shareholder increased by 0.89% to 44,065 shares [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.02 million shares as a new shareholder [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [1] - The company's main business involves the research, development, and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [1]

Core Insights - Baiyao Tai Biopharmaceutical (Guangzhou) Co., Ltd. has been established with a registered capital of 330 million yuan, focusing on drug contract manufacturing and production [1][2] Company Information - The company is wholly owned by Baiyao Tai (688177) [1] - The legal representative is Jin Weifeng, and the company is currently in operation [2] - The registered address is located in Huangpu District, Guangzhou, Guangdong Province [2] Financial Details - The registered capital is 330 million yuan, equivalent to approximately 33 million [1][2] - The company is classified as a foreign-invested limited liability company [2] Business Scope - The operational scope includes drug contract manufacturing and drug production [1][2]

Group 1 - The establishment of Bai'ao Tai Biopharmaceutical (Guangzhou) Co., Ltd. has been recently reported, with a registered capital of 330 million yuan [1] - The company's business scope includes entrusted drug production and drug manufacturing [1] - Bai'ao Tai Biopharmaceutical is fully owned by Bai'ao Tai [1]

Group 1 - The establishment of Bai'ao Tai Biopharmaceutical (Guangzhou) Co., Ltd. has been reported, with a registered capital of 330 million yuan [1] - The company's business scope includes contract manufacturing of pharmaceuticals and pharmaceutical production [1] - Bai'ao Tai Biopharmaceutical (Guangzhou) is wholly owned by Bai'ao Tai (688177) [1]

Group 1 - The core viewpoint of the news is that Baiotai Biopharmaceutical Co., Ltd. has seen a stock price increase of 5.38%, reaching 27.80 yuan per share, with a total market capitalization of 11.511 billion yuan [1] - Baiotai's main business involves the research and development, production of innovative drugs and biosimilars, with the revenue composition being 91.90% from drug sales, 6.55% from licensing, 0.90% from processing, and 0.65% from technical services [1] Group 2 - From the perspective of fund holdings, Penghua Fund has a significant position in Baiotai, with the Penghua Anze Mixed A fund holding 600 shares, accounting for 0.02% of the fund's net value [2] - The Penghua Anze Mixed A fund has a total scale of 13.306 million yuan and has achieved a year-to-date return of 2.53% [2] Group 3 - The fund managers of Penghua Anze Mixed A include Zhu Song, Zhang Jingxian, and Shi Yunchao, with Zhu Song having a tenure of 11 years and 255 days, managing assets totaling 27.86 billion yuan [3] - The best fund return during Zhu Song's tenure is 106.13%, while the worst is 0.86% [3]

Market Overview - The biopharmaceutical sector increased by 0.7% on October 29, with C禾元 leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Top Gainers in Biopharmaceutical Sector - C禾元 (688765) closed at 113.22, with a significant increase of 24.28% and a trading volume of 208,800 shares, amounting to 2.171 billion yuan [1] - 奥浦迈 (688293) closed at 62.11, rising by 9.97% with a trading volume of 24,900 shares, totaling 149 million yuan [1] - 吴帆生物 (301393) closed at 54.59, up 5.06% with a trading volume of 45,800 shares, amounting to 244 million yuan [1] Other Notable Performers - 诺思兰德 (920047) closed at 25.93, increasing by 4.09% with a trading volume of 52,000 shares, totaling 130 million yuan [1] - 沃森生物 (300142) closed at 11.78, up 3.79% with a trading volume of 521,600 shares, amounting to 614 million yuan [1] - 三生国健 (688336) closed at 61.72, increasing by 3.52% with a trading volume of 86,900 shares, totaling 526 million yuan [1] Decliners in Biopharmaceutical Sector - 百奧泰 (688177) closed at 26.70, down 2.52% with a trading volume of 21,700 shares, totaling 57.768 million yuan [2] - 派林生物 (000403) closed at 15.73, decreasing by 2.30% with a trading volume of 159,000 shares, amounting to 251 million yuan [2] - 康华生物 (300841) closed at 74.59, down 2.06% with a trading volume of 27,800 shares, totaling 208 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 399 million yuan from institutional investors, while retail investors saw a net inflow of 331 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - 辽宁成大 (600739) had a net inflow of 38.8721 million yuan from institutional investors, while retail investors had a net outflow of 15.3175 million yuan [3] - C禾元 (688765) saw a net inflow of 36.5446 million yuan from institutional investors, with retail investors experiencing a net outflow of 62.1427 million yuan [3] - 康弘药业 (002773) had a net inflow of 19.6335 million yuan from institutional investors, while retail investors faced a net outflow of 26.8166 million yuan [3]

Core Viewpoint - The company, Bai'ao Tai Biopharmaceutical Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, with no significant omissions or misleading statements [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][6]. - The report includes major accounting data and financial indicators, although specific figures are not detailed in the provided text [3][4]. - The company confirms that there were no significant changes in the financial indicators compared to previous periods [5][6]. Shareholder Information - The report includes details about the total number of ordinary shareholders and the top ten shareholders, although specific numbers are not provided [5][6]. - There are no changes reported regarding the participation of major shareholders in securities lending activities [5][6]. Other Important Information - The company has not identified any additional significant information regarding its operational performance during the reporting period [5][6]. - The financial statements include the consolidated balance sheet, profit and cash flow statements for the period from January to September 2025, all of which are unaudited [6][7].

Core Insights - Baotai (688177.SH) reported a revenue of 684 million yuan for the first three quarters of 2025, representing a year-on-year growth of 17.57% [1] - The company recorded a net loss attributable to shareholders of 224 million yuan [1] - The non-recurring net profit loss was 279 million yuan, with a basic earnings per share of -0.54 yuan [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥241,699,411.34, representing a year-on-year increase of 34.92%[3] - The total profit for the period was -¥98,875,994.44, with a net profit attributable to shareholders of -¥98,925,756.74[3] - Total operating revenue for the first three quarters of 2025 reached ¥683,587,252.74, an increase of 17.6% compared to ¥581,432,379.45 in the same period of 2024[22] - The net loss for the first three quarters of 2025 was ¥223,857,914.21, an improvement from a net loss of ¥365,319,363.66 in the same period of 2024[24] - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.54, an improvement from -¥0.88 in the same period of 2024[24] - Operating profit for the first three quarters of 2025 was a loss of ¥253.86 million, an improvement compared to a loss of ¥363.39 million in 2024, indicating a reduction in losses by about 30.2%[37] - Net profit for the first three quarters of 2025 was a loss of ¥220.97 million, compared to a loss of ¥364.79 million in 2024, reflecting a decrease in net losses by approximately 39.4%[38] Cash Flow - The net cash flow from operating activities was -¥37,178,334.97 for the quarter[3] - Cash inflow from operating activities for the first nine months was CNY 930,240,505.02, an increase from CNY 853,241,184.51 in the same period last year, representing an increase of approximately 9.1%[29] - Cash flow from operating activities for the first three quarters of 2025 was a net outflow of ¥35.84 million, an improvement from a net outflow of ¥83.74 million in 2024[40] - Cash inflow from financing activities was CNY 300,267,385.39, down from CNY 375,320,938.27 year-over-year[30] - Net cash inflow from financing activities was CNY 9,496,421.75, a significant decrease from CNY 160,414,803.15 in the previous year[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,228,538,327.05, reflecting a 1.04% increase from the end of the previous year[4] - The company's total assets increased to ¥2,228,538,327.05 from ¥2,205,537,745.47, reflecting a growth of 1.0%[19] - Total liabilities rose to ¥1,744,373,605.17, up from ¥1,497,448,743.34, marking an increase of 16.5%[19] - The company's total equity decreased to CNY 488,979,822.66 from CNY 709,951,538.12 year-over-year[34] Research and Development - Research and development expenses amounted to ¥207,916,539.08, accounting for 86.02% of the revenue, a decrease of 23.76 percentage points compared to the previous year[4] - Research and development expenses amounted to ¥556,733,175.53, slightly down from ¥599,195,843.12, indicating a focus on cost management in R&D[23] - Research and development expenses for the first three quarters of 2025 amounted to ¥560.15 million, slightly down from ¥603.01 million in 2024, indicating a focus on cost management in R&D[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,397[10] - The total equity attributable to shareholders decreased by 31.62% to ¥484,164,721.88 compared to the end of the previous year[4] - The company's equity attributable to shareholders decreased to ¥484,164,721.88 from ¥708,089,002.13, a decline of 31.7%[19] Strategic Initiatives - The company is actively exploring new product development and market expansion strategies to enhance growth prospects[14] - Future guidance indicates a commitment to improving operational metrics and financial performance in the upcoming quarters[14] - The company is also considering potential mergers and acquisitions to strengthen its market position and diversify its portfolio[14] Inventory and Receivables - Accounts receivable increased to RMB 140,209,679.67 from RMB 104,145,872.77, indicating a growth of approximately 34.6%[17] - Inventory levels rose to RMB 294,056,576.10, compared to RMB 253,095,021.19, reflecting an increase of about 16.2%[17]